News >

Mirvetuximab Soravtansine Misses Primary Endpoint in Ovarian Cancer Trial

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 01, 2019

Kathleen N.
Moore, MD
Kathleen N. Moore, MD
The antibody-drug conjugate mirvetuximab soravtansine did not improve progression-free survival (PFS) compared with chemotherapy in patients with folate receptor alpha (FRα)–positive, platinum-resistant ovarian cancer and in an overall patient population, missing the primary endpoint of the phase III FORWARD I trial.1

The median PFS was 4.3 months in the pooled group (95% CI, 3.9-5.4) with a 19.3-week duration of response. Moreover, the median PFS was 6.7 months (95% CI, 4.1-8.3) in the FORWARD I eligible group with a duration of response of 25.1 weeks.

References

  1. ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer. ImmunoGen. Published March 1, 2019. https://bit.ly/2C9kW1F. Accessed March 1, 2019.
  2. Moore KN, Matulonis UA, O’Malley DM, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): activity and safety analyses in phase I pooled expansion cohorts. J Clin Oncol. 2017;35 (suppl; abstr 5547). doi: 10.1200/JCO.2017.35.15_suppl.5547.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x